France Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market Report 2023 to 2030

France Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market Analysis

$ 3999

France Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market is projected to grow from $xx Mn in 2023 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2023 ? 2030. Increasing awareness and diagnosis, Increasing funding for medical infrastructure and high rate of multiple sclerosis prevalence (MS), unmet medical needs, advancements in drug development, Regulatory Approvals of drugs like eculizumab, inebilizumab and satralizumab , rising healthcare expenditure and growing collaborations in research and development of drugs are the major drivers for Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs Market. Major global players in Neuromyelitis Optica Spectrum Disorder (NMOSD) drugs Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark).

ID: IN10FRRD103 CATEGORY: Rare Diseases GEOGRAPHY: France AUTHOR: Gaurav Bhongale

Buy Now

France Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market Analysis Summary

France Neuromyelitis Optica Spectrum Disorder (NMOSD) Drugs Market is valued at around $11.83 Mn in 2022 and is projected to reach $17.62 Mn by 2030, exhibiting a CAGR of 5.1% during the forecast period 2023-2030.

The chronic illness known as neuromyelitis optica spectrum disorder (NMOSD) is characterised by optic neuritis, an inflammation of the optic nerve, and inflammation of the spinal cord (myelitis). The condition was once thought to be monophasic, with inflammatory bouts affecting one or both of the optic nerves and the spinal cord lasting only a few days or weeks and never repeating beyond the initial episode. According to a recent study, the majority of persons who fit the current diagnosis of NMOSD had multiple attacks spaced by remission intervals. This condition is also known as device illness. Immunosuppressive medications that reduce inflammation and stop relapses are the mainstay of treatment for NMOSD. Drugs approved for treating NMOSD are eculizumab (Soliris): An anti-complement component 5 (C5) monoclonal antibody that inhibits the complement cascade, Inebilizumab (Uplizna): A B-cell-depleting monoclonal antibody that targets the CD19 protein and Satralizumab (Enspryng): A monoclonal antibody that targets the interleukin-6 (IL-6) receptor. Emerging Therapies like fenebrutinib: A Bruton's tyrosine kinase (BTK) inhibitor currently in clinical trials and ibrutinib also in clinical trials are currently being developed. Additionally, producers of products for treating disorders of the optic nerve are teaching medical professionals about the special qualities of topical ocular corticosteroids, such as their strength and the requirement for patient-specific doses. The initiatives of various government organisations to improve the healthcare infrastructure by increasing financing will have an even greater impact on market dynamics. Major global players in Neuromyelitis Optica Spectrum Disorder (NMOSD) Therapeutics Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark).

Market Dynamics

Market Drivers

Increasing funding for medical infrastructure

A significant factor affecting the growth rate of the neuromyelitis optica spectrum disorder (NMOSD) market is the rising healthcare spending, which supports the development of its infrastructure. Additionally, producers of products for treating disorders of the optic nerve are teaching medical professionals about the special qualities of topical ocular corticosteroids, such as their strength and the requirement for patient-specific doses. The initiatives of various government organisations to improve the healthcare infrastructure by increasing financing will have an even greater impact on market dynamics.

High rate of multiple sclerosis prevalence (MS)

The increased incidence of multiple sclerosis is projected to have a significant role in the market expansion for neuromyelitis optica spectrum disorder (NMOSD). MS, an autoimmune illness where the immune system assaults healthy physiological components, results in visual loss or impairment in more than half of cases. As a result, manufacturers are expanding their capacity to make immunosuppressive medications that improve patients' quality of life. In order to better understand how Ocrevus (immunosuppressive medicine) affects persons with relapsing and progressive MS, Roche, a multinational healthcare company with headquarters in Switzerland, announced the clinical study results in September 2019.

Increasing awareness and diagnosis, unmet medical needs, and advancements in drug development all these act as market growth drivers.

Market Restraints

On the other hand, the high cost associated with the treatment will obstruct the growth rate of the market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the neuromyelitis optica spectrum disorder (NMOSD) market. Additionally, strict regulatory policies and a lack of awareness among people will restrain and further impede the growth rate of the market.

Key players

Biogen Novartis Roche Sanofi BMS AbbVie Teva Pharmaceutical Industries Acorda Therapeutics Celgene Genentech

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Market Segmentations For France Neuromyelitis Optica Spectrum Drugs (NMOSD) Market

By Type

Neuromyelitis Optica Spectrum Disorder with Aquaporin-4 Antibodies
Neuromyelitis Optica Spectrum Disorder without Aquaporin-4 Antibodies

By Treatment type

Medication
Plasma Exchange Therapy
Immunoglobulin Therapy

By Dosage form:

Tablets
Injections
Others

By Route of administration:

Oral
Parenteral
Others

By Diagnosis

Imaging tests
Blood tests
Others

By End Users

Hospitals
Specialty Clinics
Homecare
Others

By Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.